Improving the Prescription Drug Market through Transparency, Competition, and Value

“Patients with chronic conditions, such as Hepatitis C, benefit immensely when breakthrough, life-changing drugs provide a cure where none existed before. But when states are driven to create access limitations to that same drug for their Medicaid populations, we have to acknowledge something is not quite right here.”

Read more

CSRxP Statement on Launch of AstraZeneca’s Crestor

“We are glad to see that the court rejected AstraZeneca’s effort to abuse the Orphan Drug Act and restrict generic competitors to Crestor,” said John Rother. “Additional competition in the prescription drug market—including generic options—is crucial to lowering prescription drug prices and providing patients with more affordable choices.”

Read more

Campaign Discusses Market-Based Solutions to Drug Pricing on Capitol Hill

Members of the Campaign for Sustainable Rx Pricing (CSRxP) gathered on Capitol Hill to discuss market-based policy solutions to curb rising drug prices.

Read more

Drug Companies Protecting Their Monopoly To Keep Prices High

Our new board game illustrates how pharmaceutical companies have a monopoly on the current pricing system and the different ways they keep prices high.

Read more